CHAPTER 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Investment Pockets
3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
3.3.1. Bargaining Power of Suppliers
3.3.2. Threat of New Entrants
3.3.3. Threat of Substitutes
3.3.4. Competitive Rivalry
3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: CAPECITABINE MARKET, BY INDICATION
4.1. Market Overview
4.1.1 Market Size and Forecast, By Indication
4.2. Colorectal Cancer
4.2.1. Key Market Trends, Growth Factors and Opportunities
4.2.2. Market Size and Forecast, By Region
4.2.3. Market Share Analysis, By Country
4.3. Breast Cancer
4.3.1. Key Market Trends, Growth Factors and Opportunities
4.3.2. Market Size and Forecast, By Region
4.3.3. Market Share Analysis, By Country
4.4. Others
4.4.1. Key Market Trends, Growth Factors and Opportunities
4.4.2. Market Size and Forecast, By Region
4.4.3. Market Share Analysis, By Country
CHAPTER 5: CAPECITABINE MARKET, BY DRUG TYPE
5.1. Market Overview
5.1.1 Market Size and Forecast, By Drug Type
5.2. Branded
5.2.1. Key Market Trends, Growth Factors and Opportunities
5.2.2. Market Size and Forecast, By Region
5.2.3. Market Share Analysis, By Country
5.3. Generic
5.3.1. Key Market Trends, Growth Factors and Opportunities
5.3.2. Market Size and Forecast, By Region
5.3.3. Market Share Analysis, By Country
CHAPTER 6: CAPECITABINE MARKET, BY END USER
6.1. Market Overview
6.1.1 Market Size and Forecast, By End User
6.2. Hospitals
6.2.1. Key Market Trends, Growth Factors and Opportunities
6.2.2. Market Size and Forecast, By Region
6.2.3. Market Share Analysis, By Country
6.3. Homecare
6.3.1. Key Market Trends, Growth Factors and Opportunities
6.3.2. Market Size and Forecast, By Region
6.3.3. Market Share Analysis, By Country
6.4. Specialty Clinics
6.4.1. Key Market Trends, Growth Factors and Opportunities
6.4.2. Market Size and Forecast, By Region
6.4.3. Market Share Analysis, By Country
6.5. Others
6.5.1. Key Market Trends, Growth Factors and Opportunities
6.5.2. Market Size and Forecast, By Region
6.5.3. Market Share Analysis, By Country
CHAPTER 7: CAPECITABINE MARKET, BY REGION
7.1. Market Overview
7.1.1 Market Size and Forecast, By Region
7.2. North America
7.2.1. Key Market Trends and Opportunities
7.2.2. Market Size and Forecast, By Indication
7.2.3. Market Size and Forecast, By Drug Type
7.2.4. Market Size and Forecast, By End User
7.2.5. Market Size and Forecast, By Country
7.2.6. U.S. Capecitabine Market
7.2.6.1. Market Size and Forecast, By Indication
7.2.6.2. Market Size and Forecast, By Drug Type
7.2.6.3. Market Size and Forecast, By End User
7.2.7. Canada Capecitabine Market
7.2.7.1. Market Size and Forecast, By Indication
7.2.7.2. Market Size and Forecast, By Drug Type
7.2.7.3. Market Size and Forecast, By End User
7.2.8. Mexico Capecitabine Market
7.2.8.1. Market Size and Forecast, By Indication
7.2.8.2. Market Size and Forecast, By Drug Type
7.2.8.3. Market Size and Forecast, By End User
7.3. Europe
7.3.1. Key Market Trends and Opportunities
7.3.2. Market Size and Forecast, By Indication
7.3.3. Market Size and Forecast, By Drug Type
7.3.4. Market Size and Forecast, By End User
7.3.5. Market Size and Forecast, By Country
7.3.6. Germany Capecitabine Market
7.3.6.1. Market Size and Forecast, By Indication
7.3.6.2. Market Size and Forecast, By Drug Type
7.3.6.3. Market Size and Forecast, By End User
7.3.7. France Capecitabine Market
7.3.7.1. Market Size and Forecast, By Indication
7.3.7.2. Market Size and Forecast, By Drug Type
7.3.7.3. Market Size and Forecast, By End User
7.3.8. UK Capecitabine Market
7.3.8.1. Market Size and Forecast, By Indication
7.3.8.2. Market Size and Forecast, By Drug Type
7.3.8.3. Market Size and Forecast, By End User
7.3.9. Italy Capecitabine Market
7.3.9.1. Market Size and Forecast, By Indication
7.3.9.2. Market Size and Forecast, By Drug Type
7.3.9.3. Market Size and Forecast, By End User
7.3.10. Spain Capecitabine Market
7.3.10.1. Market Size and Forecast, By Indication
7.3.10.2. Market Size and Forecast, By Drug Type
7.3.10.3. Market Size and Forecast, By End User
7.3.11. Rest Of Europe Capecitabine Market
7.3.11.1. Market Size and Forecast, By Indication
7.3.11.2. Market Size and Forecast, By Drug Type
7.3.11.3. Market Size and Forecast, By End User
7.4. Asia-Pacific
7.4.1. Key Market Trends and Opportunities
7.4.2. Market Size and Forecast, By Indication
7.4.3. Market Size and Forecast, By Drug Type
7.4.4. Market Size and Forecast, By End User
7.4.5. Market Size and Forecast, By Country
7.4.6. Japan Capecitabine Market
7.4.6.1. Market Size and Forecast, By Indication
7.4.6.2. Market Size and Forecast, By Drug Type
7.4.6.3. Market Size and Forecast, By End User
7.4.7. China Capecitabine Market
7.4.7.1. Market Size and Forecast, By Indication
7.4.7.2. Market Size and Forecast, By Drug Type
7.4.7.3. Market Size and Forecast, By End User
7.4.8. Australia Capecitabine Market
7.4.8.1. Market Size and Forecast, By Indication
7.4.8.2. Market Size and Forecast, By Drug Type
7.4.8.3. Market Size and Forecast, By End User
7.4.9. India Capecitabine Market
7.4.9.1. Market Size and Forecast, By Indication
7.4.9.2. Market Size and Forecast, By Drug Type
7.4.9.3. Market Size and Forecast, By End User
7.4.10. South Korea Capecitabine Market
7.4.10.1. Market Size and Forecast, By Indication
7.4.10.2. Market Size and Forecast, By Drug Type
7.4.10.3. Market Size and Forecast, By End User
7.4.11. Rest of Asia-Pacific Capecitabine Market
7.4.11.1. Market Size and Forecast, By Indication
7.4.11.2. Market Size and Forecast, By Drug Type
7.4.11.3. Market Size and Forecast, By End User
7.5. LAMEA
7.5.1. Key Market Trends and Opportunities
7.5.2. Market Size and Forecast, By Indication
7.5.3. Market Size and Forecast, By Drug Type
7.5.4. Market Size and Forecast, By End User
7.5.5. Market Size and Forecast, By Country
7.5.6. Brazil Capecitabine Market
7.5.6.1. Market Size and Forecast, By Indication
7.5.6.2. Market Size and Forecast, By Drug Type
7.5.6.3. Market Size and Forecast, By End User
7.5.7. Saudi Arabia Capecitabine Market
7.5.7.1. Market Size and Forecast, By Indication
7.5.7.2. Market Size and Forecast, By Drug Type
7.5.7.3. Market Size and Forecast, By End User
7.5.8. South Africa Capecitabine Market
7.5.8.1. Market Size and Forecast, By Indication
7.5.8.2. Market Size and Forecast, By Drug Type
7.5.8.3. Market Size and Forecast, By End User
7.5.9. Rest of LAMEA Capecitabine Market
7.5.9.1. Market Size and Forecast, By Indication
7.5.9.2. Market Size and Forecast, By Drug Type
7.5.9.3. Market Size and Forecast, By End User
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top Winning Strategies
8.3. Product Mapping Of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top Player Positioning, 2023
CHAPTER 9: COMPANY PROFILES
9.1. F. Hoffmann-La Roche Ltd.
9.1.1. Company Overview
9.1.2. Key Executives
9.1.3. Company Snapshot
9.1.4. Operating Business Segments
9.1.5. Product Portfolio
9.1.6. Business Performance
9.1.7. Key Strategic Moves and Developments
9.2. Mylan N.V.
9.2.1. Company Overview
9.2.2. Key Executives
9.2.3. Company Snapshot
9.2.4. Operating Business Segments
9.2.5. Product Portfolio
9.2.6. Business Performance
9.2.7. Key Strategic Moves and Developments
9.3. Teva Pharmaceutical Industries Ltd.
9.3.1. Company Overview
9.3.2. Key Executives
9.3.3. Company Snapshot
9.3.4. Operating Business Segments
9.3.5. Product Portfolio
9.3.6. Business Performance
9.3.7. Key Strategic Moves and Developments
9.4. Sanofi
9.4.1. Company Overview
9.4.2. Key Executives
9.4.3. Company Snapshot
9.4.4. Operating Business Segments
9.4.5. Product Portfolio
9.4.6. Business Performance
9.4.7. Key Strategic Moves and Developments
9.5. Pfizer Inc.
9.5.1. Company Overview
9.5.2. Key Executives
9.5.3. Company Snapshot
9.5.4. Operating Business Segments
9.5.5. Product Portfolio
9.5.6. Business Performance
9.5.7. Key Strategic Moves and Developments
9.6. Dr. Reddy’s Laboratories Ltd.
9.6.1. Company Overview
9.6.2. Key Executives
9.6.3. Company Snapshot
9.6.4. Operating Business Segments
9.6.5. Product Portfolio
9.6.6. Business Performance
9.6.7. Key Strategic Moves and Developments
9.7. Novartis AG
9.7.1. Company Overview
9.7.2. Key Executives
9.7.3. Company Snapshot
9.7.4. Operating Business Segments
9.7.5. Product Portfolio
9.7.6. Business Performance
9.7.7. Key Strategic Moves and Developments
9.8. Bayer AG
9.8.1. Company Overview
9.8.2. Key Executives
9.8.3. Company Snapshot
9.8.4. Operating Business Segments
9.8.5. Product Portfolio
9.8.6. Business Performance
9.8.7. Key Strategic Moves and Developments
9.9. Eli Lilly And Company.
9.9.1. Company Overview
9.9.2. Key Executives
9.9.3. Company Snapshot
9.9.4. Operating Business Segments
9.9.5. Product Portfolio
9.9.6. Business Performance
9.9.7. Key Strategic Moves and Developments
9.10. Merck And Co., Inc.
9.10.1. Company Overview
9.10.2. Key Executives
9.10.3. Company Snapshot
9.10.4. Operating Business Segments
9.10.5. Product Portfolio
9.10.6. Business Performance
9.10.7. Key Strategic Moves and Developments
LIST OF TABLES
TABLE 1. GLOBAL CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 2. CAPECITABINE MARKET FOR COLORECTAL CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 3. CAPECITABINE MARKET FOR BREAST CANCER, BY REGION, 2024 - 2033 ($BILLION)
TABLE 4. CAPECITABINE MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 5. GLOBAL CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 6. CAPECITABINE MARKET FOR BRANDED, BY REGION, 2024 - 2033 ($BILLION)
TABLE 7. CAPECITABINE MARKET FOR GENERIC, BY REGION, 2024 - 2033 ($BILLION)
TABLE 8. GLOBAL CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 9. CAPECITABINE MARKET FOR HOSPITALS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 10. CAPECITABINE MARKET FOR HOMECARE, BY REGION, 2024 - 2033 ($BILLION)
TABLE 11. CAPECITABINE MARKET FOR SPECIALTY CLINICS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 12. CAPECITABINE MARKET FOR OTHERS, BY REGION, 2024 - 2033 ($BILLION)
TABLE 13. CAPECITABINE MARKET, BY REGION, 2024 - 2033 ($BILLION)
TABLE 14. NORTH AMERICA CAPECITABINE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 15. NORTH AMERICA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 16. NORTH AMERICA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 17. NORTH AMERICA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 18. U.S. CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 19. U.S. CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 20. U.S. CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 21. CANADA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 22. CANADA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 23. CANADA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 24. MEXICO CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 25. MEXICO CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 26. MEXICO CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 27. EUROPE CAPECITABINE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 28. EUROPE CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 29. EUROPE CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 30. EUROPE CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 31. GERMANY CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 32. GERMANY CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 33. GERMANY CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 34. FRANCE CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 35. FRANCE CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 36. FRANCE CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 37. UK CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 38. UK CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 39. UK CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 40. ITALY CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 41. ITALY CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 42. ITALY CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 43. SPAIN CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 44. SPAIN CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 45. SPAIN CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 46. REST OF EUROPE CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 47. REST OF EUROPE CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 48. REST OF EUROPE CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 49. ASIA-PACIFIC CAPECITABINE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 50. ASIA-PACIFIC CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 51. ASIA-PACIFIC CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 52. ASIA-PACIFIC CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 53. JAPAN CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 54. JAPAN CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 55. JAPAN CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 56. CHINA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 57. CHINA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 58. CHINA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 59. AUSTRALIA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 60. AUSTRALIA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 61. AUSTRALIA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 62. INDIA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 63. INDIA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 64. INDIA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 65. SOUTH KOREA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 66. SOUTH KOREA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 67. SOUTH KOREA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 68. REST OF ASIA-PACIFIC CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 69. REST OF ASIA-PACIFIC CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 70. REST OF ASIA-PACIFIC CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 71. LAMEA CAPECITABINE MARKET, BY COUNTRY, 2024 - 2033 ($BILLION)
TABLE 72. LAMEA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 73. LAMEA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 74. LAMEA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 75. BRAZIL CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 76. BRAZIL CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 77. BRAZIL CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 78. SAUDI ARABIA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 79. SAUDI ARABIA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 80. SAUDI ARABIA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 81. SOUTH AFRICA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 82. SOUTH AFRICA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 83. SOUTH AFRICA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 84. REST OF LAMEA CAPECITABINE MARKET, BY INDICATION, 2024 - 2033 ($BILLION)
TABLE 85. REST OF LAMEA CAPECITABINE MARKET, BY DRUG TYPE, 2024 - 2033 ($BILLION)
TABLE 86. REST OF LAMEA CAPECITABINE MARKET, BY END USER, 2024 - 2033 ($BILLION)
TABLE 87. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 88. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 89. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
TABLE 90. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 91. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 92. MYLAN N.V.: KEY EXECUTIVES
TABLE 93. MYLAN N.V.: COMPANY SNAPSHOT
TABLE 94. MYLAN N.V.: OPERATING SEGMENTS
TABLE 95. MYLAN N.V.: PRODUCT PORTFOLIO
TABLE 96. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 97. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 98. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 99. TEVA PHARMACEUTICAL INDUSTRIES LTD.: OPERATING SEGMENTS
TABLE 100. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 101. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 102. SANOFI: KEY EXECUTIVES
TABLE 103. SANOFI: COMPANY SNAPSHOT
TABLE 104. SANOFI: OPERATING SEGMENTS
TABLE 105. SANOFI: PRODUCT PORTFOLIO
TABLE 106. SANOFI: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 107. PFIZER INC.: KEY EXECUTIVES
TABLE 108. PFIZER INC.: COMPANY SNAPSHOT
TABLE 109. PFIZER INC.: OPERATING SEGMENTS
TABLE 110. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 111. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
TABLE 113. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 114. DR. REDDY’S LABORATORIES LTD.: OPERATING SEGMENTS
TABLE 115. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 116. DR. REDDY’S LABORATORIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 117. NOVARTIS AG: KEY EXECUTIVES
TABLE 118. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 119. NOVARTIS AG: OPERATING SEGMENTS
TABLE 120. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 121. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 122. BAYER AG: KEY EXECUTIVES
TABLE 123. BAYER AG: COMPANY SNAPSHOT
TABLE 124. BAYER AG: OPERATING SEGMENTS
TABLE 125. BAYER AG: PRODUCT PORTFOLIO
TABLE 126. BAYER AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 127. ELI LILLY AND COMPANY.: KEY EXECUTIVES
TABLE 128. ELI LILLY AND COMPANY.: COMPANY SNAPSHOT
TABLE 129. ELI LILLY AND COMPANY.: OPERATING SEGMENTS
TABLE 130. ELI LILLY AND COMPANY.: PRODUCT PORTFOLIO
TABLE 131. ELI LILLY AND COMPANY.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 132. MERCK AND CO., INC.: KEY EXECUTIVES
TABLE 133. MERCK AND CO., INC.: COMPANY SNAPSHOT
TABLE 134. MERCK AND CO., INC.: OPERATING SEGMENTS
TABLE 135. MERCK AND CO., INC.: PRODUCT PORTFOLIO
TABLE 136. MERCK AND CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 1. GLOBAL CAPECITABINE MARKET, 2024 - 2033
FIGURE 2. SEGMENTATION OF CAPECITABINE MARKET, 2024 - 2033
FIGURE 3. TOP INVESTMENT POCKET IN CAPECITABINE MARKET
FIGURE 4. MODERATE BARGAINING POWER OF BUYERS
FIGURE 5. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 6. MODERATE THREAT OF NEW ENTRANTS
FIGURE 7. LOW THREAT OF SUBSTITUTION
FIGURE 8. HIGH COMPETITIVE RIVALRY
FIGURE 9. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALCAPECITABINE MARKET
FIGURE 10. GLOBAL CAPECITABINE MARKET SEGMENTATION, BY INDICATION
FIGURE 11. CAPECITABINE MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 12. CAPECITABINE MARKET FOR BREAST CANCER, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 13. CAPECITABINE MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 14. GLOBAL CAPECITABINE MARKET SEGMENTATION, BY DRUG TYPE
FIGURE 15. CAPECITABINE MARKET FOR BRANDED, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 16. CAPECITABINE MARKET FOR GENERIC, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 17. GLOBAL CAPECITABINE MARKET SEGMENTATION, BY END USER
FIGURE 18. CAPECITABINE MARKET FOR HOSPITALS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 19. CAPECITABINE MARKET FOR HOMECARE, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 20. CAPECITABINE MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 21. CAPECITABINE MARKET FOR OTHERS, BY COUNTRY, 2024 - 2033 ($BILLION)
FIGURE 22. TOP WINNING STRATEGIES, BY YEAR, 2021-2023*
FIGURE 23. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2021-2023*
FIGURE 24. TOP WINNING STRATEGIES, BY COMPANY, 2021-2023*
FIGURE 25. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 26. COMPETITIVE DASHBOARD
FIGURE 27. COMPETITIVE HEATMAP: CAPECITABINE MARKET
FIGURE 28. TOP PLAYER POSITIONING, 2023
FIGURE 29. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 30. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 31. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 32. MYLAN N.V.: NET SALES, 2021-2023 ($BILLION)
FIGURE 33. MYLAN N.V.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 34. MYLAN N.V.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 35. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 36. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 37. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 38. SANOFI: NET SALES, 2021-2023 ($BILLION)
FIGURE 39. SANOFI: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 40. SANOFI: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 41. PFIZER INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 42. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 43. PFIZER INC.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 44. DR. REDDY’S LABORATORIES LTD.: NET SALES, 2021-2023 ($BILLION)
FIGURE 45. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 46. DR. REDDY’S LABORATORIES LTD.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 47. NOVARTIS AG: NET SALES, 2021-2023 ($BILLION)
FIGURE 48. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 49. NOVARTIS AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 50. BAYER AG: NET SALES, 2021-2023 ($BILLION)
FIGURE 51. BAYER AG: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 52. BAYER AG: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 53. ELI LILLY AND COMPANY.: NET SALES, 2021-2023 ($BILLION)
FIGURE 54. ELI LILLY AND COMPANY.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 55. ELI LILLY AND COMPANY.: REVENUE SHARE, BY REGION, 2023 (%)
FIGURE 56. MERCK AND CO., INC.: NET SALES, 2021-2023 ($BILLION)
FIGURE 57. MERCK AND CO., INC.: REVENUE SHARE, BY SEGMENT, 2023 (%)
FIGURE 58. MERCK AND CO., INC.: REVENUE SHARE, BY REGION, 2023 (%)
